Trials / Recruiting
RecruitingNCT05775523
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Ascendis Pharma Endocrinology Division A/S · Industry
- Sex
- All
- Age
- 1 Year – 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | No intervention | No intervention |
Timeline
- Start date
- 2023-03-20
- Primary completion
- 2033-03-01
- Completion
- 2033-03-01
- First posted
- 2023-03-20
- Last updated
- 2026-02-04
Locations
27 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05775523. Inclusion in this directory is not an endorsement.